Literature DB >> 14572326

Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part I: Design.

Virgil A Marple1, Daryl L Roberts, Francisco J Romay, Nicholas C Miller, Keith G Truman, Michiel Van Oort, Bo Olsson, Michael J Holroyd, Jolyon P Mitchell, Dieter Hochrainer.   

Abstract

A new cascade impactor has been designed specifically for pharmaceutical inhaler testing. This impactor, called the Next Generation Pharmaceutical Impactor (NGI), has seven stages and is intended to operate at any inlet flow rate between 30 and 100 L/min. It spans a cut size (D50) range from 0.54-microm to 11.7-microm aerodynamic diameter at 30 L/min and 0.24 microm to 6.12 microm at 100 L/min. The aerodynamics of the impactor follow established scientific principles, giving confident particle size fractionation behavior over the design flow range. The NGI has several features to enhance its utility for inhaler testing. One such feature is that particles are deposited on collection cups that are held in a tray. This tray is removed from the impactor as a single unit, facilitating quick sample turn-around times if multiple trays are used. For accomplishing drug recovery, the user can add up to approximately 40 mL of an appropriate solvent directly to the cups. Another unique feature is a micro-orifice collector (MOC) that captures in a collection cup extremely small particles normally collected on the final filter in other impactors. The particles captured in the MOC cup can be analyzed in the same manner as the particles collected in the other impactor stage cups. The user-friendly features and the aerodynamic design principles together provide an impactor well suited to the needs of the inhaler testing community.

Mesh:

Substances:

Year:  2003        PMID: 14572326     DOI: 10.1089/089426803769017659

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  27 in total

1.  Effect of sampling volume on dry powder inhaler (DPI)-emitted aerosol aerodynamic particle size distributions (APSDs) measured by the Next-Generation Pharmaceutical Impactor (NGI) and the Andersen eight-stage cascade impactor (ACI).

Authors:  Hlack Mohammed; Daryl L Roberts; Mark Copley; Mark Hammond; Steven C Nichols; Jolyon P Mitchell
Journal:  AAPS PharmSciTech       Date:  2012-06-08       Impact factor: 3.246

2.  Temporally and Spatially Resolved x-ray Fluorescence Measurements of in-situ Drug Concentration in Metered-Dose Inhaler Sprays.

Authors:  Daniel J Duke; Alan L Kastengren; Nicholas Mason-Smith; Yang Chen; Paul M Young; Daniela Traini; David Lewis; Daniel Edgington-Mitchell; Damon Honnery
Journal:  Pharm Res       Date:  2015-11-12       Impact factor: 4.200

Review 3.  In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review.

Authors:  Jolyon Mitchell; Steve Newman; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2007-12-21       Impact factor: 3.246

4.  The abbreviated impactor measurement (AIM) concept: part 1--Influence of particle bounce and re-entrainment-evaluation with a "dry" pressurized metered dose inhaler (pMDI)-based formulation.

Authors:  J P Mitchell; M W Nagel; V Avvakoumova; H MacKay; R Ali
Journal:  AAPS PharmSciTech       Date:  2009-03-12       Impact factor: 3.246

5.  The contribution of different formulation components on the aerosol charge in carrier-based dry powder inhaler systems.

Authors:  Susan Hoe; Daniela Traini; Hak-Kim Chan; Paul M Young
Journal:  Pharm Res       Date:  2010-03-31       Impact factor: 4.200

Review 6.  Minimizing variability of cascade impaction measurements in inhalers and nebulizers.

Authors:  Matthew Bonam; David Christopher; David Cipolla; Brent Donovan; David Goodwin; Susan Holmes; Svetlana Lyapustina; Jolyon Mitchell; Steve Nichols; Gunilla Pettersson; Chris Quale; Nagaraja Rao; Dilraj Singh; Terrence Tougas; Mike Van Oort; Bernd Walther; Bruce Wyka
Journal:  AAPS PharmSciTech       Date:  2008-02-28       Impact factor: 3.246

7.  Influence of polymeric carrier on the disposition and retention of 20(R)-ginsenoside-rg3-loaded swellable microparticles in the lung.

Authors:  Xiuhua Wang; Xiao Zhang; Linlin Fan; Huan He; Xiaofei Zhang; Yuyang Zhang; Shirui Mao
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

8.  De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products.

Authors:  Sharon Shui Yee Leung; Patricia Tang; Qi Tony Zhou; Zhenbo Tong; Cassandra Leung; Janwit Decharaksa; Runyu Yang; Hak-Kim Chan
Journal:  AAPS J       Date:  2015-07-23       Impact factor: 4.009

9.  Good Cascade Impactor Practice (GCIP) and considerations for "in-use" specifications.

Authors:  S C Nichols; J P Mitchell; C M Shelton; D L Roberts
Journal:  AAPS PharmSciTech       Date:  2013-01-24       Impact factor: 3.246

10.  A novel high-speed imaging technique to predict the macroscopic spray characteristics of solution based pressurised metered dose inhalers.

Authors:  Nicolas A Buchmann; Daniel J Duke; Sayed A Shakiba; Daniel M Mitchell; Peter J Stewart; Daniela Traini; Paul M Young; David A Lewis; Julio Soria; Damon Honnery
Journal:  Pharm Res       Date:  2014-06-17       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.